“…Covalent anthracycline immunochemotherapeutics have been designed to selectively ''target'' chemotherapeutic delivery, and evoke potent ex vivo cytotoxic anti-neoplastic potency against several neoplastic cell types including mammary adenocarcinoma (anti-HER2/neu, anti-epidermal growth factor receptor [EGFR]), 7,26 colon adenocarcinoma (anti-CEA) 36 ; multiple myeloma (CD38 + , MC/CAR), 28 B-lymphoma, 32 melanoma, 27,29,35 gastric carcinoma, 39 colon carcinoma, 37 pulmonary carcinoma, 40 and other neoplastic cell types (CEA). 34,35 In direct accord with their level of in vitro efficacy, similar covalent anthracycline immunochemotherapeutics reduce in vivo tumor burden and prolong survival against human xenografts of gastric carcinoma, 39 breast cancer, 33 CD38 positive MC/CAR multiple myeloma, 28 B-lymphoma, 32 T-cell lymphoma, 41 colon carcinoma, 33,[42][43][44] ovarian carcinoma, 42 pulmonary carcinoma, 33 metastatic melanoma, 27,29 hepatocellular carcinoma, 31 and intracerebral small-cell lung carcinoma. [45][46][47] In part these findings correlate with the recognized additive and synergistic levels of cytotoxic anti-neoplastic potency of anti-HER2/neu (inhibited HER2/neu function) in concert with conventional chemotherapeutics such as cyclophosphamide, 48,49 docetaxel, 48 doxorubicin, 48,49 etoposide, 48 methotrexate, 48 paclitaxel, 48,...…”